Table 1 Demographic and laboratory findings between AAV patients with and without HP
| Â | Total AAV | Newly diagnosed AAV | Relapsed AAV | ||||||
|---|---|---|---|---|---|---|---|---|---|
HP (n = 30) | Non-HP (n = 633) | p-values | HP (n = 20) | Non-HP (n = 538) | p-values | HP (n = 10) | Non-HP (n = 95) | p-values | |
Characteristics | |||||||||
 Age, years | 71.1 ± 8.0 | 70.2 ± 13.7 | 0.509 | 70.8 ± 8.5 | 70.9 ± 13.4 | 0.349 | 71.9 ± 7.5 | 66.3 ± 15.0 | 0.425 |
 Sex, male/female, n (%) | 18/12 | 280/353 | 0.095 | 12/8 | 280/353 | 0.177 | 6/4 | 38/57 | 0.315 |
AAV classification, n (%) | |||||||||
 GPA | 15 (50) | 126 (20) | 0.0003 | 10 (50) | 89 (17) | 0.0007 | 5 (50) | 37 (39) | 0.516 |
 MPA | 15 (50) | 309 (60) | 0.341 | 10 (50) | 345 (64) | 0.238 | 5 (50) | 36 (38) | 0.507 |
 EGPA | 0 | 126 (20) | 0.003 | 0 | 104 (19) | 0.345 | 0 | 22 (23) | 0.116 |
Type of ANCA, n (%) | |||||||||
 PR3 | 6 (20) | 78 (12) | 0.254 | 5 (25) | 47 (9) | 0.030 | 1 (10) | 31 (32) | 0.277 |
 MPO | 23 (77) | 473 (75) | 0.999 | 14 (70) | 421 (78) | 0.409 | 9 (90) | 52 (55) | 0.042 |
 Seronegative | 1 (3) | 82 (13) | 0.159 | 1 (5) | 70 (13) | 0.494 | 0 | 12 (13) | 0.599 |
Laboratory data | |||||||||
 White blood cells, /μL | 9618 ± 4124 | 12398 ± 6425 | 0.009 | 10510 ± 4628 | 12729 ± 6533 | 0.129 | 7834 ± 2069 | 10528 ± 5435 | 0.084 |
 Neutrophils, /μL | 8017 ± 4189 | 8456 ± 4487 | 0.586 | 8635 ± 4889 | 8569 ± 4588 | 0.936 | 6842 ± 2102 | 7830 ± 3848 | 0.523 |
 Lymphocytes, /μL | 1045 ± 630 | 1326 ± 748 | 0.020 | 1269 ± 632 | 1357 ± 756 | 0.826 | 587 ± 310 | 1153 ± 679 | 0.002 |
 C-reactive protein, mg/dL | 5.22 ± 5.59 | 7.12 ± 6.27 | 0.505 | 7.35 ± 5.70 | 7.73 ± 6.33 | 0.892 | 3.97 ± 4.86 | 3.68 ± 4.70 | 0.674 |
 Serum creatinine, mg/dL | 0.79 ± 0.36 | 1.44 ± 1.55 | 0.005 | 0.78 ± 0.33 | 1.45 ± 1.57 | 0.019 | 0.82 ± 0.44 | 1.39 ± 1.43 | 0.111 |
 eGFR | 75.7 ± 24.8 | 57.2 ± 31.9 | 0.0005 | 75.8 ± 23.0 | 57.1 ± 32.1 | 0.004 | 76.5 ± 29.5 | 57.8 ± 31.3 | 0.077 |